Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with
PDCD1
adverse event
metastatic renal cell carcinoma
nivolumab
single nucleotide polymorphism
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
05 07 2022
05 07 2022
Historique:
received:
18
05
2022
revised:
28
06
2022
accepted:
30
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Single nucleotide polymorphisms (SNPs) reportedly influence the effect of nivolumab in metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the relationship between the clinical outcomes of patients with mRCC and SNPs in programmed cell death protein 1 (PD-1) protein-coding gene (
Identifiants
pubmed: 35885987
pii: genes13071204
doi: 10.3390/genes13071204
pmc: PMC9324515
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Cancers (Basel). 2020 Dec 13;12(12):
pubmed: 33322163
J Urol. 2008 Oct;180(4):1262-6; discussion 1266
pubmed: 18707708
Clin Genitourin Cancer. 2020 Dec;18(6):477-488
pubmed: 32732112
Clin Immunol. 2020 Feb;211:108319
pubmed: 31794865
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184
pubmed: 30670497
J Oncol Pharm Pract. 2020 Jun;26(4):814-822
pubmed: 31495293
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Rheumatol Int. 2016 Jan;36(1):33-44
pubmed: 26232179
Urol Case Rep. 2019 Dec 14;29:101105
pubmed: 31908963
Clin Exp Immunol. 2015 Jun;180(3):452-7
pubmed: 25682896
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808740
Curr Med Chem. 2018;25(11):1327-1339
pubmed: 28403786
Br J Cancer. 2018 May;118(10):1296-1301
pubmed: 29695768
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
Cancers (Basel). 2020 Nov 26;12(12):
pubmed: 33255938
Int J Clin Oncol. 2017 Aug;22(4):629-634
pubmed: 28382562
Immunotherapy. 2017 Aug;9(9):701-707
pubmed: 28649876
Front Immunol. 2021 Jan 14;11:606721
pubmed: 33519815
Int J Clin Oncol. 2020 Aug;25(8):1543-1550
pubmed: 32394047
Cancers (Basel). 2021 Mar 18;13(6):
pubmed: 33803602
Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S11-4
pubmed: 22274654
Mol Clin Oncol. 2019 Sep;11(3):320-324
pubmed: 31341623
Urol Oncol. 2019 Jun;37(6):355.e21-355.e29
pubmed: 30935847
Oncotarget. 2015 Aug 7;6(22):18933-44
pubmed: 25895129
Medicine (Baltimore). 2016 Dec;95(52):e5749
pubmed: 28033288
Nat Genet. 2002 Dec;32(4):666-9
pubmed: 12402038
J Hum Genet. 2005;50(5):264-266
pubmed: 15883854
Int J Clin Oncol. 2020 Aug;25(8):1533-1542
pubmed: 32519026
Hum Immunol. 2010 Dec;71(12):1209-13
pubmed: 20837075
Immunogenetics. 2018 Feb;70(2):73-86
pubmed: 28642997
Sci Rep. 2017 Mar 23;7:45124
pubmed: 28332580
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
JAMA Oncol. 2016 Jan;2(1):46-54
pubmed: 26562159